The Impact of COVID-19 Regulations on Adherence to Recombinant Human Growth Hormone Therapy: Evidence from Real-World Data
Worldwide regulations during COVID-19 positively and negatively impacted self-management in paediatric patients with chronic medical conditions. We investigated the impact of regulations on adherence to recombinant human growth hormone (r-hGH) therapy in paediatric patients with growth disorders, us...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Endocrines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-396X/4/1/17 |
| _version_ | 1827750123017338880 |
|---|---|
| author | Paula van Dommelen Rosa Maria Baños Lilian Arnaud Quentin Le Masne Ekaterina Koledova |
| author_facet | Paula van Dommelen Rosa Maria Baños Lilian Arnaud Quentin Le Masne Ekaterina Koledova |
| author_sort | Paula van Dommelen |
| collection | DOAJ |
| description | Worldwide regulations during COVID-19 positively and negatively impacted self-management in paediatric patients with chronic medical conditions. We investigated the impact of regulations on adherence to recombinant human growth hormone (r-hGH) therapy in paediatric patients with growth disorders, using real-world adherence data extracted March 2019–February 2020 (before COVID-19) and March 2020–February 2021 (during COVID-19) from the easypod™ connect ecosystem. Data from three measures of regulations were analysed: stringency index (SI), school closure and stay-at-home. The mean SI, and the proportion of days with required school closure or stay-at-home during COVID-19 were categorised as high versus medium/low based on the 75th percentile. Adherence was categorised as optimal (≥85%) versus suboptimal (<85%). Adherence data were available for 8915 patients before and 7606 patients during COVID-19. A high SI (mean ≥68) and a high proportion of required school closure (≥88%) resulted in an increase in the proportion of optimal adherence during COVID-19 versus pre-COVID-19 (<i>p</i> < 0.001). Stay-at-home requirements showed no statistically significant effect (<i>p</i> = 0.13). Stringent COVID-19 regulations resulted in improved adherence to r-hGH therapy in patients with growth disorders, supported by connected digital health technologies. Insights into patient behavior during this time are useful to understand potential influences and strategies to improve long-term adherence to r-hGH. |
| first_indexed | 2024-03-11T06:38:08Z |
| format | Article |
| id | doaj.art-bd0a09bb1e52495884967eb5ff970ed5 |
| institution | Directory Open Access Journal |
| issn | 2673-396X |
| language | English |
| last_indexed | 2024-03-11T06:38:08Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Endocrines |
| spelling | doaj.art-bd0a09bb1e52495884967eb5ff970ed52023-11-17T10:47:03ZengMDPI AGEndocrines2673-396X2023-03-014119420410.3390/endocrines4010017The Impact of COVID-19 Regulations on Adherence to Recombinant Human Growth Hormone Therapy: Evidence from Real-World DataPaula van Dommelen0Rosa Maria Baños1Lilian Arnaud2Quentin Le Masne3Ekaterina Koledova4The Netherlands Organization for Applied Scientific Research TNO, P.O. Box 2215, NL-2301 CE Leiden, The NetherlandsDepartment of Personality, Evaluation and Psychological Treatment, Faculty of Psychology, University of Valencia, Av. de Blasco Ibáñez, 21, 46010 Valencia, SpainConnected Health & Devices, Global Healthcare Operations, Ares Trading S.A., 1262 Eysins, Switzerland (an affiliate of Merck KGaA, Darmstadt, Germany)Connected Health & Devices, Global Healthcare Operations, Ares Trading S.A., 1262 Eysins, Switzerland (an affiliate of Merck KGaA, Darmstadt, Germany)Global Medical Affairs Cardiometabolic & Endocrinology, Merck Healthcare KGaA, Frankfurter Str. 250, F135/001, 64293 Darmstadt, GermanyWorldwide regulations during COVID-19 positively and negatively impacted self-management in paediatric patients with chronic medical conditions. We investigated the impact of regulations on adherence to recombinant human growth hormone (r-hGH) therapy in paediatric patients with growth disorders, using real-world adherence data extracted March 2019–February 2020 (before COVID-19) and March 2020–February 2021 (during COVID-19) from the easypod™ connect ecosystem. Data from three measures of regulations were analysed: stringency index (SI), school closure and stay-at-home. The mean SI, and the proportion of days with required school closure or stay-at-home during COVID-19 were categorised as high versus medium/low based on the 75th percentile. Adherence was categorised as optimal (≥85%) versus suboptimal (<85%). Adherence data were available for 8915 patients before and 7606 patients during COVID-19. A high SI (mean ≥68) and a high proportion of required school closure (≥88%) resulted in an increase in the proportion of optimal adherence during COVID-19 versus pre-COVID-19 (<i>p</i> < 0.001). Stay-at-home requirements showed no statistically significant effect (<i>p</i> = 0.13). Stringent COVID-19 regulations resulted in improved adherence to r-hGH therapy in patients with growth disorders, supported by connected digital health technologies. Insights into patient behavior during this time are useful to understand potential influences and strategies to improve long-term adherence to r-hGH.https://www.mdpi.com/2673-396X/4/1/17adherenceCOVID-19growth disordersinjection devicelockdownrecombinant human growth hormone (r-hGH) |
| spellingShingle | Paula van Dommelen Rosa Maria Baños Lilian Arnaud Quentin Le Masne Ekaterina Koledova The Impact of COVID-19 Regulations on Adherence to Recombinant Human Growth Hormone Therapy: Evidence from Real-World Data Endocrines adherence COVID-19 growth disorders injection device lockdown recombinant human growth hormone (r-hGH) |
| title | The Impact of COVID-19 Regulations on Adherence to Recombinant Human Growth Hormone Therapy: Evidence from Real-World Data |
| title_full | The Impact of COVID-19 Regulations on Adherence to Recombinant Human Growth Hormone Therapy: Evidence from Real-World Data |
| title_fullStr | The Impact of COVID-19 Regulations on Adherence to Recombinant Human Growth Hormone Therapy: Evidence from Real-World Data |
| title_full_unstemmed | The Impact of COVID-19 Regulations on Adherence to Recombinant Human Growth Hormone Therapy: Evidence from Real-World Data |
| title_short | The Impact of COVID-19 Regulations on Adherence to Recombinant Human Growth Hormone Therapy: Evidence from Real-World Data |
| title_sort | impact of covid 19 regulations on adherence to recombinant human growth hormone therapy evidence from real world data |
| topic | adherence COVID-19 growth disorders injection device lockdown recombinant human growth hormone (r-hGH) |
| url | https://www.mdpi.com/2673-396X/4/1/17 |
| work_keys_str_mv | AT paulavandommelen theimpactofcovid19regulationsonadherencetorecombinanthumangrowthhormonetherapyevidencefromrealworlddata AT rosamariabanos theimpactofcovid19regulationsonadherencetorecombinanthumangrowthhormonetherapyevidencefromrealworlddata AT lilianarnaud theimpactofcovid19regulationsonadherencetorecombinanthumangrowthhormonetherapyevidencefromrealworlddata AT quentinlemasne theimpactofcovid19regulationsonadherencetorecombinanthumangrowthhormonetherapyevidencefromrealworlddata AT ekaterinakoledova theimpactofcovid19regulationsonadherencetorecombinanthumangrowthhormonetherapyevidencefromrealworlddata AT paulavandommelen impactofcovid19regulationsonadherencetorecombinanthumangrowthhormonetherapyevidencefromrealworlddata AT rosamariabanos impactofcovid19regulationsonadherencetorecombinanthumangrowthhormonetherapyevidencefromrealworlddata AT lilianarnaud impactofcovid19regulationsonadherencetorecombinanthumangrowthhormonetherapyevidencefromrealworlddata AT quentinlemasne impactofcovid19regulationsonadherencetorecombinanthumangrowthhormonetherapyevidencefromrealworlddata AT ekaterinakoledova impactofcovid19regulationsonadherencetorecombinanthumangrowthhormonetherapyevidencefromrealworlddata |